Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Clinicoeconomics and Outcomes Research : CEOR|December 5, 2017
Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in ItalyValentina Lorenzoni, Fabio Baccetti, Stefano Genovese, et al.
Diabetes Care|October 28, 2003
Semiquantitative analysis of the histopathological features of the neuropathic foot ulcer: effects of pressure reliefAlberto Piaggesi, Paolo Viacava, Loredana Rizzo, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|May 1, 2013
Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experienceRoberto Anichini, Sabrina Cosimi, Alberto Di Carlo, et al.
Acta Diabetologica|February 12, 2015
Incidence and risk factors for severe and symptomatic hypoglycemia in type 1 diabetes. Results of the HYPOS-1 studyCarlo B Giorda, Alessandro Ozzello, Sandro Gentile, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|June 3, 2019
Impact of severe and symptomatic hypoglycemia on quality of life and fear of hypoglycemia in type 1 and type 2 diabetes. Results of the Hypos-1 observational studyMaria Chiara Rossi, Antonio Nicolucci, Alessandro Ozzello, et al.
Diabetes Research and Clinical Practice|July 13, 2024
Profiles of sulfonylurea use in Diabetes Mellitus type 2: an analysis of clinical practice over the last 10 yearsFabio Baccetti, Cristiano Crisafulli, Francesco Andreozzi, et al.
Diabetes, Obesity & Metabolism|March 10, 2026
Identifying Predictors of Early Treatment Intensification in Individuals With Type 2 Diabetes Treated With GLP-1 Receptor Agonists: A Machine Learning-Based Analysis of a Large Real World CohortPierpaolo Falcetta, Rita Zilich, Fabio Baccetti, et al.
The Journal of Clinical Endocrinology and Metabolism|April 8, 2025
Treatment intensification strategies and metabolic outcomes in individuals with type 2 diabetes on GLP-1 RA therapyPierpaolo Falcetta, Rita Zilich, Fabio Baccetti, et al.
Cardiovascular Diabetology|February 28, 2025
Lipid-lowering therapy and LDL target attainment in type 2 diabetes: trends from the Italian Associations of Medical Diabetologists databaseAntonio Rossi, Davide Masi, Rita Zilich, et al.
Frontiers in Pharmacology|June 16, 2022
Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort StudyGiuseppe Roberto, Anna Girardi, Francesco Barone-Adesi, et al.
Pageof 2